Summary:
The Preventing Early Renal Loss (PERL) study is a clinical trial designed to test whether the medication allopurinol can prevent or slow down kidney disease in people with type 1 diabetes. About 480 people with type 1 diabetes will participate in PERL. The study will last 3 years, and kidney function will be measured periodically to see if this treatment is effective:
- Study participants will take the study medication (allopurinol or placebo) each day for 3 years.
- At the beginning, middle and end of the study (a total of 4 times), a special test of kidney function, lasting about 4 hours, is performed at a PERL center.
- Other study visits (12 over 3 years) take about 1 hour and can be done at a PERL center (if you live nearby) or at a clinic or office close to your home.
- All study-related procedures and tests are provided at no charge. Participants receive a small payment for their time. Parking and transportation costs may be reimbursed.
Qualified Participants Must:
• Be diagnosed with Type 1 (insulin-treated) diabetes for at least 8 years
•
Be age 18 years or older
•
Show early signs of decreased kidney function on blood and/or urine tests